ArticleScientific reports2026
7SK-enriched exosomes suppress the cancer phenotypes in human lung cancer cells: insights from 2D and microfluidic 3D in vitro models.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spheroids and organoids to study long noncoding RNAs in cancer: how they could replace animal models.Cancer metastasis reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer, being the top cause of global cancer-related mortality, calls for effective treatments. RN7SK (7SK) is a long non-coding RNA (lncRNA) that plays a significant role in the regulation of gene transcription and thereby controls essential cellular activities. Limited evidence supports the anticancer potential of 7SK, and its suppressive effects have not been tested against lung cancer. This study explored the anticancer effects of RN7SK (7SK), a long non-coding RNA known to regulate gene transcription, through exosome-mediated delivery in lung cancer cells. Treatment with exosome-loaded 7SK (Exo-7SK) significantly elevated 7SK levels in non-small-cell lung cancer cells and suppressed key cancer traits. Exo-7SK reduced cell viability and proliferation, promoted apoptosis, and inhibited migration and invasion by shifting gene expression away from epithelial-mesenchymal transition. It also impaired spheroid formation and reduced spheroid dispersion and viability in 3D microfluidic cultures. In conclusion, our findings highlight the cancer-suppressive potential of exosome-mediated 7SK delivery against lung cancer, demonstrating significant efficacy in both 2D and 3D culture models. These observations warrant further confirmation in future studies employing advanced designs and clinically relevant models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.